GlassScriptPhysician profile
Ronald Ford Bruton
NPI 1033114566
$2,873.84
in general payments reported to CMS, 2019-2025
30 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $458 · 2021: $425 · 2022: $367 · 2023: $311 · 2024: $275 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.29 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $537.08 | 2019-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $421.59 | 2022-2025 | |
| Abbvie INC. | $261.50 | 2021-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $234.16 | 2021-2025 | Spravato |
| Glaxosmithkline, LLC. | $185.17 | 2020-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $179.68 | 2019-2025 | |
| Genzyme Corporation | $123.14 | 2025 | |
| Axsome Therapeutics, INC. | $118.91 | 2025 | Auvelity |
| Novo Nordisk INC | $101.92 | 2019-2021 | |
| Lilly USA, LLC | $100.35 | 2020-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.00 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $57.65 | 2023-2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $49.82 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.72 | 2024-2025 | Caplyta |
| Abbott Laboratories | $38.76 | 2022-2023 | Freestyle Libre 2 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $36.99 | 2023 | Puraply |
| Melinta Therapeutics, LLC | $34.69 | 2019 | |
| Allergan, INC. | $30.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.07 | 2022-2024 | Farxiga |
| Eisai INC. | $28.75 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.91 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $25.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.17 | 2019 | |
| Amarin Pharma, INC. | $20.19 | 2021 | |
| Axonics, INC. | $19.96 | 2023 | Axonics |
| Averitas Pharma INC. | $16.34 | 2024 | Qutenza |
| Astellas Pharma US INC | $15.82 | 2019 | |
| Gilead Sciences, INC. | $12.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.74 | 2025 | Voquezna |
| Radius Health, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bruton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.